Resource-sparing and cost-effective strategies in current management of breast cancer

被引:6
作者
Munshi, Anusheel [1 ]
机构
[1] Tata Mem Hosp, Dept Radiat Oncol, Bombay 400012, Maharashtra, India
关键词
Breast cancer; resource sparing; cost effective; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL PATIENTS; POSTMENOPAUSAL WOMEN; CONSERVING THERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; TAMOXIFEN; TRASTUZUMAB; LONG; RADIOTHERAPY;
D O I
10.4103/0973-1482.52797
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the leading cause of death in women throughout the world. There have been significant advances in the practice of breast oncology over the past few years. However, most of these advances have an associated price tag or are resource intensive. The present article discusses means to achieve cost-effectiveness in the treatment of breast cancer, while retaining the benefits of the modern anticancer approaches.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 44 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Use of radiation treatment units in breast cancer.: Changes in the last 15 years [J].
Algara Lopez, Manuel ;
Sanz Latiesas, Xavier ;
Foro Arnalot, Palmira ;
Lacruz Bassols, Marti ;
Reig Castillejo, Anna ;
Lozano Galan, Joan ;
Membrive Conejo, Ismael ;
Quera Jordana, Jaume ;
Rodriguez de Dios, Nuria .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (01) :47-51
[3]  
[Anonymous], 1993, Lancet, V341, P1293
[4]   Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer [J].
Baselga, Jose ;
Perez, Edith A. ;
Pienkowski, Tadeusz ;
Bell, Richard .
ONCOLOGIST, 2006, 11 :4-12
[5]  
Baum M, 2002, LANCET, V359, P2131
[6]   Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial [J].
Castiglione-Gertsch, M ;
O'Neill, A ;
Price, KN ;
Goldhirsch, A ;
Coates, AS ;
Colleoni, M ;
Nasi, ML ;
Bonetti, M ;
Gelber, RD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (24) :1833-1846
[7]   Three-week accelerated radiation therapy (ART) schedule with a concomitant in-field boost as treatment for early stage breast cancer [J].
Chadha, M. ;
Woode, R. ;
Sillanpaa, J. ;
Feldman, S. ;
Boolbol, S. ;
Furhang, E. ;
Harrison, L. B. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03) :S137-S137
[8]   The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry [J].
Chen, SQ ;
Chou, WH ;
Blouin, RA ;
Mao, ZP ;
Humphries, LL ;
Meek, C ;
Neill, JR ;
Martin, WL ;
Hays, LR ;
Wedlund, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) :522-534
[9]   Long-term medical costs of postmenopausal breast cancer therapy [J].
Cocquyt, V ;
Moeremans, K ;
Annemans, L ;
Clarys, P ;
Van Belle, S .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1057-1063
[10]  
Cohen EE, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.0758